Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A BariMaria Christina Cox

Abstract

Improved treatment have modified survival outcome in patients with diffuse large B-cell lymphoma (DLBCL) and altered the importance of previously recognized prognostic markers. To evaluate International Prognostic Index (IPI) score before and after rituximab introduction and to validate the absolute lymphocyte count (ALC)/revised International Prognostic Index (R-IPI) model, we carried out a retrospective analysis on a total of 831 patients with DLBCL. Our results show that IPI lost its discriminating power with the introduction of rituximab. The analysis of our second set allowed us to validate the ALC/R-IPI model. The R-IPI and ALC/R-IPI could still be used for designing clinical trials, but both have difficulty recognizing a high percentage of poor prognosis patients, though it remains an important goal of a good prognostic model considering the modest impact of salvage treatments on survival. A new model on the basis of significant variables in the rituximab era and built on a large database of patients treated with rituximab is urgently needed. As prognostic models are changing with the efficacy and mechanisms of action of treatment utilized, looking for a new prognostic score is a never-ending story in which researchers a...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Dec 21, 2000·Statistics in Medicine·H C van Houwelingen
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Izidore S Lossos, Daniel Morgensztern
Feb 1, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P G GobbiUNKNOWN Gruppo Italiano Studio Linfomi
Sep 18, 2008·Leukemia & Lymphoma·Maria Christina CoxMaria Antonietta Aloe-Spiriti

❮ Previous
Next ❯

Citations

Jul 1, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C OnalE Ozyar
Jun 7, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Myriam SasanelliEmmanuel Itti
Sep 3, 2010·Leukemia & Lymphoma·Jan Delabie
Sep 27, 2013·Leukemia & Lymphoma·Alberto Valencia-HipόlitoMario I Vega
Feb 1, 2011·Leukemia & Lymphoma·Mary J NinanPankaj Gupta
Jun 10, 2015·Cancer Causes & Control : CCC·Adam J OlszewskiJorge J Castillo
Apr 7, 2015·Clinical Lymphoma, Myeloma & Leukemia·Carlos PanizoUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea GELTAMO Spanish Cooperative Group
Dec 6, 2011·Clinical Lymphoma, Myeloma & Leukemia·Ling-Ping ChenMing-Sun Yu
Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lu HeWei Xu
Feb 21, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Hajira IlyasSally F Barrington

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.